Published in J Exp Clin Cancer Res on November 22, 2013
miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res (2014) 1.38
Exposure to endocrine disruptor induces transgenerational epigenetic deregulation of microRNAs in primordial germ cells. PLoS One (2015) 1.16
miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res (2014) 1.12
MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res (2014) 1.07
MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res (2014) 0.95
A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res (2015) 0.95
Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. J Exp Clin Cancer Res (2014) 0.94
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res (2016) 0.94
Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res (2015) 0.92
MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1. J Exp Clin Cancer Res (2015) 0.89
MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma. Sci Rep (2015) 0.87
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. J Exp Clin Cancer Res (2014) 0.86
Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells. J Exp Clin Cancer Res (2014) 0.85
MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon) (2015) 0.83
miR-497 expression, function and clinical application in cancer. Oncotarget (2016) 0.79
Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response. Int J Mol Sci (2015) 0.79
Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation. J Exp Clin Cancer Res (2015) 0.79
The Role of MicroRNAs and Their Targets in Osteoarthritis. Curr Rheumatol Rep (2016) 0.79
MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers. PPAR Res (2017) 0.78
Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway. J Exp Clin Cancer Res (2016) 0.78
Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers. Int J Epidemiol (2015) 0.78
SENP3 regulates the global protein turnover and the Sp1 level via antagonizing SUMO2/3-targeted ubiquitination and degradation. Protein Cell (2015) 0.77
Decreased brain-expressed X-linked 4 (BEX4) expression promotes growth of oral squamous cell carcinoma. J Exp Clin Cancer Res (2016) 0.76
EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. J Exp Clin Cancer Res (2015) 0.76
MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res (2016) 0.75
Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression. Curr Genomics (2017) 0.75
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. J Exp Clin Cancer Res (2016) 0.75
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell (2008) 4.57
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
HDAC family: What are the cancer relevant targets? Cancer Lett (2008) 4.17
MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res (2010) 3.57
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 3.11
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem (2008) 2.72
Epigenetics in cancer: what's the future? Oncology (Williston Park) (2011) 2.70
The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res (2007) 2.54
Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell (2012) 2.53
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood (2011) 2.09
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev (2009) 1.91
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci U S A (2006) 1.82
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology (2009) 1.76
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun (2008) 1.74
miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer (2012) 1.72
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell (2012) 1.65
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology (2012) 1.55
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis (2010) 1.55
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
The functional significance of microRNA-145 in prostate cancer. Br J Cancer (2010) 1.48
miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer (2010) 1.42
Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta (2010) 1.41
Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res (2011) 1.40
Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology (2012) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene (2011) 1.33
Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem (2010) 1.31
DNA methylation silences miR-132 in prostate cancer. Oncogene (2012) 1.27
Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res (2011) 1.27
Cancer research: past, present and future. Nat Rev Cancer (2011) 1.24
MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J (2012) 1.24
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol (2011) 1.20
CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut (2012) 1.17
MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol (2010) 1.15
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics (2011) 1.08
Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol (2012) 1.04
The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol (2012) 1.03
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog (2012) 1.00
YY1 restrained cell senescence through repressing the transcription of p16. Biochim Biophys Acta (2008) 0.97
Epigenetic architecture and miRNA: reciprocal regulators. Epigenomics (2010) 0.91
miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma. Oral Dis (2012) 0.89
Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol (2008) 0.87
Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep (2010) 0.84
Cocktail of eternity: HDAC meets miR. Blood (2012) 0.81
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics (2011) 0.80
Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67
Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell (2006) 3.62
Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem (2003) 2.30
Design and synthesis of 3d-4f metal-based zeolite-type materials with a 3D nanotubular structure encapsulated "water" pipe. J Am Chem Soc (2004) 2.30
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem (2009) 2.24
Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE (2003) 2.12
Effects of an ad libitum low-fat, high-carbohydrate diet on body weight, body composition, and fat distribution in older men and women: a randomized controlled trial. Arch Intern Med (2004) 2.08
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A (2008) 2.02
Low-kilovoltage multi-detector row chest CT in adults: feasibility and effect on image quality and iodine dose. Radiology (2004) 1.88
MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci (2008) 1.80
Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (2002) 1.77
The functional contrariety of JNK. Mol Carcinog (2007) 1.77
Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer (2011) 1.69
(-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res (2006) 1.60
Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. J Biol Chem (2003) 1.53
Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology (2007) 1.51
Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells. Stem Cells (2010) 1.48
Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer Prev Res (Phila) (2013) 1.45
Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell (2005) 1.45
The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett (2006) 1.43
The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol (2002) 1.37
Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc Natl Acad Sci U S A (2012) 1.37
Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell (2010) 1.35
The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem (2005) 1.34
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33
ERK1 and ERK2 regulate embryonic stem cell self-renewal through phosphorylation of Klf4. Nat Struct Mol Biol (2012) 1.30
Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res (2008) 1.30
Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res (2008) 1.29
Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One (2010) 1.27
[6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res (2009) 1.26
Inducible covalent posttranslational modification of histone H3. Sci STKE (2005) 1.26
Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res (2009) 1.26
Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J (2007) 1.22
Small heat shock protein alphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. Biochem Biophys Res Commun (2006) 1.21
Mitogen- and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res (2008) 1.20
Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res (2005) 1.20
Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res (2003) 1.20
RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem (2007) 1.19
Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog (2008) 1.17
Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A (2010) 1.16
p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Mol Cell Biol (2007) 1.15
Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev (2007) 1.14
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res (2008) 1.14
MiR-17 modulates osteogenic differentiation through a coherent feed-forward loop in mesenchymal stem cells isolated from periodontal ligaments of patients with periodontitis. Stem Cells (2011) 1.13
Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol (2003) 1.12
Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci (2004) 1.12
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of cefixime in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.12
The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat Struct Mol Biol (2005) 1.12
Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis (2007) 1.11
Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.11
Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Syst Rev (2006) 1.11
The structural basis of R-spondin recognition by LGR5 and RNF43. Genes Dev (2013) 1.11
Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem (2002) 1.10
The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res (2005) 1.10
Human alphaA- and alphaB-crystallins prevent UVA-induced apoptosis through regulation of PKCalpha, RAF/MEK/ERK and AKT signaling pathways. Exp Eye Res (2004) 1.10
Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res (2004) 1.10
Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis (2012) 1.10
T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J Biol Chem (2010) 1.09
A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res (2009) 1.07
Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res (2010) 1.07
Absorption and enterohepatic circulation of baicalin in rats. Life Sci (2005) 1.07
Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis (2008) 1.07
MST1 promotes apoptosis through phosphorylation of histone H2AX. J Biol Chem (2010) 1.07
Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One (2012) 1.07
Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation. J Biol Chem (2002) 1.06
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res (2012) 1.06
Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res (2006) 1.05